Because HDAC5 has been shown to mediate tamoxifen resistance in HR-positive breast cancer [127], it may be worth developing and testing class II HDAC inhibitors for overcoming resistance in advanced-stage HR-positive breast cancer. The gene discussed is HDAC5; the disease is breast carcinoma.